This means that inflammation (TNF-α and IFN-γ) can maintain IL-8 secretion by gastric cancer cells and that this can become inhibited by CAM by inhibiting NF-κB activation and AP-1 binding in the IL-8 gene promoter region in gastric cancer cells. The gene discussed is IFNG; the disease is gastric cancer.